Rapid, inexpensive, universal, on-site, pan-cancer monitoring of therapy effectiveness; ultimately an inexpensive, universal, pan-cancer screening test.
Early identification of hyper-progressive disease or any inactive therapy and switching to an effective therapy can be lifesaving!
AN ELECTRODE BASED METER THAT GENERATES A DIGITAL READOUT BASED ON THE AMOUNT OF CANCER DNA IN A PERSON’S BLOOD
THE "aiELECTRODE" IS SELECTIVELY SENSITIVE TO THE ALTERED METHYLATION PATTERN THAT IS CHARACTERISTIC OF ALL TYPES OF CANCER DNA TESTED.
“…tumor cells generally exhibit genome-wide hypomethylation and localized
Zhang W, Xu J
Biomark Res. 2017; 5: 1. (Also many others.)
Thus, the identification of epigenetic alterations “…improved cancer diagnosis and effective treatments”
Zhang W1, Xu J1.
Biomark Res. 2017; 5: 1.
Watch your treatment work!
Target, Kill and Confirm.
Typically, it takes 3-6 months for scans to show if a cancer is shrinking. "Pseudo-progression" is the term used when scans are wrong, showing an increase in size despite effective therapy. Since this is possible, patients typically remain on immuno therapy for approximately 6 months even if it is not working. Side effects, even death, can occur due to these therapies which cost $60,00-120,000.
TheraScape provides a true reading of cancer DNA from a simple blood test. The first use of TheraScape will be in trials of new drugs. Pharma wants to know early if a drug is working. Clinical trial research use is not FDA regulated. A new publication documents how such testing may reduce the patients required to prove benefit by over 80%.
CLIA lab(s) will inexpensively provide the testing to doctors and patients so every person can be sure their therapy is working.
Current “personalized medicine” predicts which therapy will work for a cancer patient, unfortunately, like most predictions, it is inaccurate. For advanced cancers, although it improves the odds, more often it is wrong than right.
aiGENE does not predict, it MEASURES. This “in-persona evaluation™” will provides accurate evaluation of immunotherapy before a second dose. TheraScape will enable an immediate and lifesaving switch.
Ultimately every oncologist will be able to do this test in their office and we believe will do it on all eligible patients before every new round of therapy.